Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
Posted
Vandana Singh (via Benzinga)
Moderna announces plans to reduce R&D spending by $1.1 billion by 2027, focusing on ten key products. Analysts highlight near-term challenges, lowered price targets, and a delayed breakeven to 2028, with optimism around Moderna's oncology pipeline and long-term platform potential.
Latest Ratings for MRNA
DateFirmActionFromTo Mar 2022Deutsche BankMaintainsHold Feb 2022Morgan StanleyMaintainsEqual-Weight Feb 2022SVB LeerinkMaintainsUnderperform
View More Analyst Ratings for MRNA
View the Latest Analyst Ratings
read more
